Geron Corporation (GERN)

NASDAQ: GERN · IEX Real-Time Price · USD
4.600
-0.070 (-1.50%)
At close: Jul 19, 2024, 4:00 PM
4.640
+0.040 (0.87%)
After-hours: Jul 19, 2024, 7:59 PM EDT
-1.50%
Market Cap 2.73B
Revenue (ttm) 520,000
Net Income (ttm) -201.40M
Shares Out 593.13M
EPS (ttm) -0.35
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,122,921
Open 4.685
Previous Close 4.670
Day's Range 4.590 - 4.765
52-Week Range 1.640 - 5.340
Beta 0.48
Analysts Strong Buy
Price Target 6.93 (+50.65%)
Earnings Date Aug 8, 2024

About GERN

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquarte... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 30, 1996
Employees 141
Stock Exchange NASDAQ
Ticker Symbol GERN
Full Company Profile

Financial Performance

In 2023, Geron's revenue was $237,000, a decrease of -60.23% compared to the previous year's $596,000. Losses were -$184.13 million, 29.8% more than in 2022.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for GERN stock is "Strong Buy." The 12-month stock price forecast is $6.93, which is an increase of 50.65% from the latest price.

Price Target
$6.93
(50.65% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Geron to Announce Second Quarter 2024 Financial Results on August 8, 2024

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that it will release its second quarter 2024 financial results and...

3 days ago - Business Wire

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggr...

4 weeks ago - Business Wire

Geron Stock Soars on FDA Approval of Drug for Patients With Rare Blood Cancers

Geron (GERN) shares skyrocketed over 19% in intraday trading Friday after the Food and Drug Administration (FDA) approved the biopharma company's drug Rytelo for those with rare blood cancers.

6 weeks ago - Investopedia

Geron Corp stock opened 25% up on Friday: here's why

Geron Corp (NASDAQ: GERN) opened about 25% up on Friday after securing an FDA approval for “imetelstat”.  Here's what it means for Geron stock The Food & Drug Administration approved its lead asset as...

6 weeks ago - Invezz

Very good news for Geron stock price: now what?

Geron Corporation (NASDAQ: GERN) stock price went vertical on Friday as investors cheered the latest actions by the Food and Drug Administration (FDA). After closing at $3.90 on Thursday, the stock su...

6 weeks ago - Invezz

Geron shares surge after U.S. FDA approves blood disorder drug

Shares of Geron rose almost 16% on Friday before market, a day after getting its first approval from the U.S. Food and Drug Administration for a drug to treat transfusion-dependent anemia in patients ...

6 weeks ago - Reuters

Geron Announces FDA Approval of RYTELO™ (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that...

6 weeks ago - Business Wire

Geron Corporation Reports First Quarter 2024 Financial Results and Business Highlights

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to t...

2 months ago - Business Wire

Geron to Announce First Quarter 2024 Financial Results on May 2, 2024

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its first quarter 2024 financial results a...

3 months ago - Business Wire

Geron to Participate at Upcoming Investor Conferences in April

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron's Chairman and Chief Executi...

3 months ago - Business Wire

Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the pricing of an underwritten offering consisting of 41,999,99...

4 months ago - Business Wire

Can Geron Corporation maintain momentum following FDA's backing?

Friday saw an unprecedented surge in the stock of Geron Corporation (NASDAQ:GERN), with shares ending the day up a staggering 92%. This surge, marking a historic milestone for the company, was ignited...

4 months ago - Invezz

Geron's stock soars 95% after FDA advisory panel votes in favor of blood-disorder drug

Geron Corp.'s stock rose 95% Friday, after an advisory panel to the Food and Drug Administration voted 12-to-2 in favor of the company's blood-disorder drug imetelstat and said its benefits outweigh t...

4 months ago - Market Watch

Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to t...

4 months ago - Business Wire

Geron's blood disorder drug gets FDA advisers' backing

Advisers to the U.S. Food and Drug Administration on Thursday voted in favor of Geron's blood disorder drug, stating that, based on late-stage trial data, the benefits outweigh treatment associated ri...

4 months ago - Reuters

US FDA staff flags concerns about Geron's anemia treatment

The U.S. health regulator's staff on Tuesday flagged concerns that the late-stage trial data on Geron's anemia drug does not show whether the risks of treatment with imetelstat are outweighed by the p...

4 months ago - Reuters

Geron Corporation Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to t...

5 months ago - Business Wire

Geron to Announce Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its fourth quarter and full-year 2023 fina...

5 months ago - Business Wire

Geron to Participate in the B. Riley Securities Virtual Oncology Conference

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron's Chairman and Chief Executi...

6 months ago - Business Wire

Geron Announces IMerge Phase 3 Presentations at ASH Highlighting Significant Durability of Transfusion Independence and Breadth of Effect Across MDS Subgroups with Imetelstat in Lower Risk MDS

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced presentations of data from its IMerge Phase 3 clinical trial ev...

7 months ago - Business Wire

Geron Announces Fifty Percent Enrollment in the Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat in Patients with Relapsed/Refractory Myelofibrosis

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced achievement of fifty percent enrollment in the Phase 3 IMpactMF...

8 months ago - Business Wire

Geron Announces Publication in The Lancet of Results from the IMerge Phase 3 Clinical Trial Evaluating Imetelstat in Lower Risk MDS

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced publication in The Lancet of results from the IMerge Phase 3 tr...

8 months ago - Business Wire

Geron Corporation Announces Appointment of Gaurav Aggarwal, M.D., to its Board of Directors

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the appointment of Gaurav Aggarwal, M.D., to the Company's Boar...

8 months ago - Business Wire

Geron to Participate at Upcoming Investor Conferences in November

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron's Chairman and Chief Executi...

9 months ago - Business Wire

Geron IMerge Phase 3 Presentations at Upcoming ASH Annual Meeting Reinforce Significant Durability and Breadth of Effect of Imetelstat in Lower Risk MDS

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the publication of abstracts from the IMerge Phase 3 clinical t...

9 months ago - Business Wire